Kevin Kinter

Kevin Kinter has extensive work experience in the pharmaceutical industry. Kevin started their career in 1995 as a Research Scientist at Cardiovascular Diagnostics Inc, where they developed an in-house immunoassay program and analyzed protein reactivity. In 1996, they worked as a Research Associate at Duke University Medical Center, where they conducted HPLC analysis of steroids and synthesized compounds for pre-clinical cancer studies. From 1997 to 1998, they served as an Adjunct Professor at Virginia Commonwealth University. In 1998, they became a Process Engineer II at bioMerieux, where they led projects on failure investigations, validations, and scale-up projects. Kevin optimized the formulation of a liquid emulsion sensor and led the transfer of a product from R&D to Manufacturing.

Kevin'slong-term work experience was at Pfizer and GlaxoSmithKline Consumer Healthcare, starting in 2001. During their time there, they held various roles such as Senior Principal Scientist, Lead Formulator, Technical Lead, and Scientific Mentor. Kevin was responsible for initiating prototypes, conducting formulation experiments, leading scientific teams, and consulting with senior leadership. Kevin also worked on projects related to softgel formulations, PK screening trials, and the development of dual-action tablets. Additionally, they contributed to innovation initiatives and conducted technology landscaping and due diligence evaluations. Kevin'stenure at Pfizer and GlaxoSmithKline Consumer Healthcare ended in 2021.

In 2022, Kevin Kinter joined Pegasus Laboratories, Inc. as the Senior Director of Formulations.

Kevin Kinter has a strong educational background in the field of Chemistry. Kevin started their education journey at Douglas S. Freeman High School from 1981 to 1984. After completing high school, they attended James Madison University from 1985 to 1988, where they earned their Bachelor of Science degree in Chemistry. Kevin then pursued further studies at the University of Florida from 1989 to 1993, earning their PhD in Organic Chemistry. Kevin'sdoctoral research focused on Carbonyls as Free-Radical Precursors. Following their PhD, they conducted post-doctoral research at Duke University from 1993 to 1995, specializing in the synthesis of Photo-Labile Serine Protease Inhibitors.